CHARACTERISTICS OF SIROLIMUS-ASSOCIATED INTERSTITIAL PNEUMONITIS IN RENAL TRANSPLANT PATIENTS
Transplantation2001Vol. 72(5), pp. 787–790
Citations Over TimeTop 10% of 2001 papers
Emmanuel Morélon, M. Stern, Dominique Israël‐Biet, Jean-Michel Corréas, Claire Danel, Marie‐France Mamzer, Marie‐Noelle Péraldi, Henri Kreis
Abstract
Sirolimus is very probably responsible for interstitial pneumonitis on the following grounds: (a) occurrence of pneumonitis during sirolimus therapy; (b) absence of any other causes; and (c) resolution within 3 months of sirolimus discontinuation or dose reduction. Sirolimus should now be added to the list of possible causes of pulmonary complications after renal transplantation. Discontinuation or dose reduction of sirolimus led to complete and lasting resolution of symptoms.
Related Papers
- → Reversible Sirolimus-associated Pneumonitis after Heart Transplantation(2005)33 cited
- → Switch to Everolimus for Sirolimus-Induced Pneumonitis in a Liver Transplant Recipient—Not All Proliferation Signal Inhibitors Are the Same: A Case Report(2007)30 cited
- Sirolimus-induced pneumonitis in a renal transplant recipient(2010)
- Types Research of Discontinuation of a Crime(2007)